Drugs / Id-KLH
Id-KLH
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00001512 | Sep 1996 → Mar 2010 | follicular lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002787 | Mar 1996 → Dec 2002 | plasma cell myeloma | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00302861 | Mar 2006 → ? | B-cell chronic lymphocytic leukemia | Genitope Corporation | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00621036 | Oct 2007 → Dec 2008 | central nervous system neoplasm, lymphoma, lymphoproliferative syndrome, small intestine cancer | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00510471 | May 2007 → ? | non-Hodgkin lymphoma | Genitope Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00041730 | Jul 2002 → ? | non-Hodgkin lymphoma | Favrille | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00574886 | Aug 2000 → Mar 2002 | lymphoma | University of Nebraska | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Id-KLH | “Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF” NCT00510471 ↗4“Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF” NCT00302861 ↗ |
| Known as | autologous immunoglobulin idiotype-KLH conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00621036 ↗ |
| Known as | FavId | “Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma” NCT00041730 ↗ |
| Known as | Recombinant Idiotype Conjugated to KLH | “Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF” NCT00510471 ↗ |
| Modality | Vaccine | “patients will receive an autologous Id vaccine administered in combination with GM-CSF.” NCT00001512 ↗ |
| Route | Subcutaneous | “Id-KLH (0.5 mg) is administered subcutaneously.” NCT00001512 ↗ |